299 results about "Membrane protein" patented technology

The invention discloses a method for promoting dissolution of eggshell membrane protein and preparing chelated calcium through high-pressure crushing. Comprising the following steps: separating and drying eggshells and eggshell membranes of egg shells, and respectively carrying out superfine grinding to obtain eggshell powder and eggshell membrane powder; adding water into the eggshell membrane powder, carrying out high-pressure homogenization, and centrifuging to obtain an eggshell membrane solution; adding eggshell powder into the eggshell membrane solution, adjusting the pH value to 1-3, and adding pepsase for reaction; after the reaction, adjusting the pH value of the eggshell membrane solution to 6.5-7.5, and adding trypsin for reaction; and after the reaction, inactivating the enzyme, centrifuging to take a supernatant, adding absolute ethyl alcohol into the supernatant for alcohol precipitation, and centrifuging to obtain a precipitate, namely the chelated calcium. The technical problem that the eggshell membrane protein is difficult to dissolve out is solved, and a new way is provided for industrial extraction of the eggshell membrane soluble protein.

The present invention relates to the field of lentiviral delivery. Specifically provided are a mutated vesicular virus envelope protein and the use thereof in lentiviral vector packaging.

The invention discloses an all-optical three-dimensional scanning confocal fluorescent microscopic imaging device and an implementation method thereof. According to the invention, through a deep learning driven adaptive regulation and control method, CNN is adopted to process spatial distribution data and dynamically regulate and control a phase hologram and the light intensity and phase compensation of a laser, so that the focal point of exciting light is subjected to aberration-free axial displacement, a bidirectional parallel optical scanning track of a two-dimensional scanning system is optimized, and all-optical three-dimensional scanning is realized; lSTM and TCN are combined to obtain a time sequence dependency relationship, a laser light source, an adjustable diaphragm, an electric focus-adjustable lens and a photoelectric detector are integrally controlled, efficient synchronization and automatic operation and high-speed axial focusing adjustment are realized, errors and time sequence mismatch are eliminated, optical characteristics of different samples and environmental interference are automatically adapted, and high-quality imaging is kept. The robustness and the applicable scene range of the system are improved; the method is used for model biological embryo real-time tracking, intracellular signal molecule dynamic visualization, cell membrane protein migration and aggregation observation and intracellular organelle interaction tracking.

The invention relates to a recombinant bacterium for overexpressing uranyl binding protein and application of the recombinant bacterium, and belongs to the technical field of microorganisms. Bacterial outer membrane protein and uranyl binding protein are expressed in host bacteria, and the uranyl binding protein is anchored on an outer membrane of recombinant bacteria through the bacterial outer membrane protein, so that the uranyl binding protein anchored on the bacterial outer membrane can adsorb uranyl ions. Meanwhile, the invention finds that the expression quantity of the uranyl binding protein can be increased by performing fusion expression on the uranyl binding protein by using LPP-OMPA, so that the adsorption effect of uranyl ions is improved. The recombinant bacterium is prepared into a freeze-dried capsule product, and the freeze-dried capsule product can penetrate through a stomach barrier and is accurately delivered to intestinal tracts so as to realize uranyl ion adsorption.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

The invention belongs to the technical field of antibodies, and discloses an antibody for resisting novel coronavirus envelope protein or an antigen binding fragment thereof and application thereof. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; a heavy chain of the antibody or the antigen binding fragment thereof comprises: a heavy chain variable region, wherein the heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3; a light chain of the antibody or the antigen binding fragment thereof comprises a light chain variable region, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody or the antigen binding fragment thereof can be used for detecting the existence or the level of the novel coronavirus envelope protein in a sample, detecting the novel coronavirus and diagnosing diseases related to novel coronavirus infection.

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.

Provided herein are transmembrane proteins containing a cytokine or a functional portion thereof, such as an interleukin or a functional portion thereof. In some aspects, the disclosure further relates to engineered cells and compositions comprising the transmembrane proteins and methods for their administration to subjects. In some embodiments, the cells engineered to contain the transmembrane protein, such as immune cells, further contain a genetically engineered recombinant receptor, such as a chimeric antigen receptor (CAR). In some embodiments, features of the transmembrane proteins, engineered cells, and methods and uses thereof provide for improved treatment of diseases or disorders.

The invention discloses a preparation method of a monomeric protein and hydrophobic transmembrane protein complex, which comprises the following steps: 1) preparing a protein A containing the monomeric protein, the C end of the monomeric protein in the protein A having a connection sequence for connecting with the hydrophobic transmembrane protein; the connecting sequence comprises at least two amino acids; preparing a protein B containing a hydrophobic transmembrane protein monomer; and 2) connecting the protein A with the protein B, and polymerizing the hydrophobic transmembrane protein monomers in the plurality of protein B to form the hydrophobic transmembrane protein, thereby obtaining the monomeric protein and hydrophobic transmembrane protein complex.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The invention relates to a transmembrane protein and transmembrane protein interaction prediction method, computer equipment and a storage medium, and the method comprises the steps: inputting an amino acid sequence 1 of protein 1 and an amino acid sequence 2 of protein 2 into a transmembrane prediction neural network, and when an output result identifies that the two proteins are transmembrane proteins, determining the transmembrane protein interaction between the two proteins; screening an extracellular amino acid fragment sequence 1 of the protein 1 and an extracellular amino acid fragment sequence 2 of the protein 2 from output results of the transmembrane prediction neural network; the extracellular amino acid fragment sequence 1 and the extracellular amino acid fragment sequence 2 are input into a trained attention mechanism model, an interaction score is obtained, and the interaction score is used for representing the interaction possibility of the protein 1 and the protein 2. According to the method, the interaction between the transmembrane protein and the transmembrane protein is automatically determined in a computer mode, and excessive manpower and material resources do not need to be consumed.

Fusion proteins containing a targeting sequence, an exosporium protein, or an exosporium protein fragment that targets the fusion protein to the exosporium of a Bacillus cereus family member are provided. Recombinant Bacillus cereus family members expressing such fusion proteins are also provided. Genetically inactivated Bacillus cereus family members and recombinant Bacillus cereus family members that overexpress exosporium proteins are also provided. Seeds coated with the recombinant Bacillus cereus family members and methods for using the recombinant Bacillus cereus family members (e.g., for stimulating plant growth) are also provided. Various modifiations of the recombinant Bacillus cereus family members that express the fusion proteins are further provided. Fusion proteins comprising a spore coat protein and a protein or peptide of interest, recombinant bacteria that express such fusion proteins, seeds coated with such recombinant bacteria, and methods for using such recombinant bacteria (e.g., for stimulating plant growth) are also provided.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

This disclosure relates to a recombinant adenovirus comprising a polynucleotide encoding DENV envelope protein and a polynucleotide encoding ferritin heavy chain protein, and uses thereof. This disclosure also provides a recombinant adenovirus comprising a polynucleotide encoding DENV (Dengue Virus) envelope protein and a polynucleotide encoding ferritin heavy chain protein, and a vaccine composition for preventing DENV infection comprising the recombinant adenovirus as an effective ingredient.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None

The application relates to a hybridoma cell strain 1B6A2 secreting an anti-fish T lymphocyte surface membrane protein CD28 monoclonal antibody, the hybridoma cell strain 1B6A2 is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202291, and the preservation date is May 5, 2022. The application provides a powerful tool for simulating a second signal in vitro and exploring a CD28-mediated T cell adaptive immune response mechanism.

To provide methods for treating viral infections including SARS-CoV-2, and to provide polymers for use in such treatments.SOLUTION: Provided are improved amphiphilic comb-type polymers with well-controlled molecular weights, structures, and end groups, and hydrophilic backbones with regularly arranged hydrophobic substituents. The polymers self-assemble in an aqueous environment to form core-corona nanoparticles that are capable of disrupting envelope proteins of a virus and can further encapsulate antiviral drugs or their prodrugs. Regularly arranged targeting groups can also mediate the attachment of the nanoparticles to an envelope of the virus.SELECTED DRAWING: Figure 2

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention discloses a lysosome targeted degradation system based on a DNA phase separation aggregate as well as a preparation method and application of the lysosome targeted degradation system, and belongs to the technical field of biological medicine and nanotechnology. The lysosome targeted degradation system based on the DNA phase separation aggregate comprises an RNA-DNA tetrahedral framework with a cohesive end, the RNA-DNA tetrahedral framework is formed by self-assembly of a core chain and an edge chain through complementary base pairing, the edge chain is a DNA-RNA chimeric oligonucleotide chain, and the DNA-RNA chimeric oligonucleotide chain is a DNA-RNA chimeric oligonucleotide chain. One or more sections of RNA ribonucleotide sequences which can be specifically recognized and cut by RNase H enzyme are embedded in the sequence, and the tail end of the RNA ribonucleotide sequence is modified with a cohesive tail end for driving phase separation and a cell membrane anchoring group; the RNA-DNA tetrahedral framework is modified with an aptamer of a targeted membrane protein. After entering cells, the system is subjected to liquid-liquid phase separation in a lysosome acid environment through interaction of cohesive ends, a micron-sized large-size aggregate is formed in situ, the residence time of a nano-drug in the lysosome is prolonged, and efficient degradation of target membrane protein is realized.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

Provided herein are compositions comprising a muscle (cardiac and / or skeletal) cell targeting peptide linked to or inserted into a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n-mer-Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors with engineered capsid or envelope proteins are provided, along with uses thereof.

Antibodies and other molecules including an antigen binding region of an antibody that immunospecifically binds to a surface unit or a transmembrane unit of a Human endogenous retrovirus-K (HERV-K) Env protein are provided. The antibodies and other molecules typically include six complementarity determining regions (CDRs). In preferred forms the antibodies and other molecules immunospecifically bind to the amino acid sequence SEQ ID NO:223 and / or 224. Chimeric antigen receptors (CAR) formed using the provided antibodies are also provided, as are cell expressing the CAR. Methods of detecting HERV-K Env, and use thereof of various other methods such as diagnostic methods are also provided. Method of treatment for HERV-K Env protein-related diseases and disorders are also provided.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

A vaccine for use in the prophylaxis and / or treatment of a diseaseThe present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

The invention relates to the technical field of organelle separation, and provides a method for rapid purification of peroxisome and oxidation regulation analysis of ultra-long chain fatty acid. The method comprises the following steps: introducing a nucleic acid sequence for coding a fusion protein into a target cell to obtain a cell material, the fusion protein comprising a truncated sequence derived from a peroxisome membrane protein and a tag sequence for affinity purification; taking the cell material as a sample, and separating the peroxisome with the fusion protein from the cell by utilizing an affinity ligand on the basis of a high affinity binding principle. Therefore, according to the method disclosed by the invention, the peroxisome can be rapidly and efficiently enriched, and the whole purification process can be completed within 30 minutes, so that the experimental period is greatly shortened; core protein components of target organelles can be efficiently reserved, and the metabolic activity of peroxisome can be maintained through a complete membrane structure and an internal environment; meanwhile, the same purified sample can synchronously support proteome and metabolome analysis, and direct association of'protein-metabolism 'data is realized.

To provide methods of identifying new substrates for proteases and methods of using these substrates in a variety of therapeutic, diagnostic and prophylactic indications.SOLUTION: The invention relates generally to: polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA); activatable antibodies and other large molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator; and methods of making these polypeptides that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and methods of use in a variety of therapeutic, diagnostic and prophylactic indications.SELECTED DRAWING: Figure 4A